Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.

@article{Ramphal1992VancomycinIN,
  title={Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.},
  author={Reuben Ramphal and Michael Bolger and David J. Oblon and Robert J. Sherertz and J. David Malone and Kenneth H Rand and M Gilliom and Joseph W. Shands and Barnett S. Kramer},
  journal={Antimicrobial agents and chemotherapy},
  year={1992},
  volume={36 5},
  pages={
          1062-7
        }
}
The use of vancomycin as part of the initial antibiotic therapy of febrile neutropenic patients has become a controversial issue. Some studies support its incorporation in the initial regimen, and others suggest that vancomycin can be added later. We examined this issue in a prospective, randomized trial. We randomized 127 febrile neutropenic patients to receive either ceftazidime alone or ceftazidime plus vancomycin as the initial empiric antibiotic treatment. We added vancomycin to the… CONTINUE READING
Highly Cited
This paper has 55 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Aztreonam for febrile neutropenia in patients with beta-lactam allergy.

Transplant infectious disease : an official journal of the Transplantation Society • 2014
View 1 Excerpt

Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2003

56 Citations

05'94'99'05'11'17
Citations per Year
Semantic Scholar estimates that this publication has 56 citations based on the available data.

See our FAQ for additional information.